23680-84-4 Bulk Price Global Manufacturer 2026
- Industrial Purity: Consistent supply of ≥99% purity material suitable for API synthesis.
- Commercial Terms: Competitive FOB pricing structures with scalable volume discounts.
- Market Outlook: Stable demand forecast for quinazoline derivatives through 2026.
In the landscape of pharmaceutical manufacturing, the reliability of key building blocks determines the efficiency of downstream drug production. 2-Chloro-6,7-dimethoxyquinazolin-4-amine (CAS: 23680-84-4) stands as a critical API intermediate used primarily in the synthesis of antihypertensive agents such as Prazosin. As supply chains evolve, procurement managers require partners who offer not just chemical availability, but technical transparency and scalable capacity. NINGBO INNO PHARMCHEM CO.,LTD. has established itself as a premier global manufacturer capable of meeting these rigorous demands through advanced process chemistry and robust quality assurance protocols.
This technical overview analyzes the synthesis routes, quality specifications, and commercial frameworks necessary for securing reliable supply of this essential Quinazoline derivative. We examine the factors influencing the bulk price trends and provide a forecast for the market trajectory leading into 2026.
Technical Specifications and Synthesis Route
Understanding the chemical profile of CAS 23680-84-4 is vital for quality control during drug substance manufacturing. The compound, also known chemically as 2-Chloro-4-amino-6,7-dimethoxyquinazoline, features a quinazoline core substituted with chloro and dimethoxy groups. This specific arrangement facilitates nucleophilic substitution reactions required to form the final active pharmaceutical ingredient.
Our manufacturing process utilizes optimized cyclization conditions to ensure high reaction yields and minimal impurity profiles. The production involves the condensation of appropriate anthranilic acid derivatives followed by chlorination. Strict control over reaction temperature and pH during the workup phase is essential to maintain industrial purity standards. Below are the standard technical specifications expected for pharmaceutical-grade batches:
| Parameter | Specification |
|---|---|
| CAS Number | 23680-84-4 |
| Molecular Formula | C10H10ClN3O2 |
| Molecular Weight | 239.66 g/mol |
| Appearance | White to Off-White Powder |
| Purity (HPLC) | ≥ 99.0% |
| Packing | 25kg Fiber Drum or Bag |
When sourcing high-purity 2-Chloro-6,7-dimethoxyquinazolin-4-amine, buyers should verify the Certificate of Analysis (COA) against these parameters. Impurities such as unreacted starting materials or over-chlorinated byproducts can significantly impact downstream coupling reactions. NINGBO INNO PHARMCHEM CO.,LTD. employs rigorous HPLC and NMR testing to ensure every batch meets the stringent requirements for custom synthesis projects and large-scale API production.
FOB Price Trends and Min.Order Requirements
The commercial viability of procuring CAS 23680-84-4 depends heavily on understanding Free On Board (FOB) pricing dynamics. Prices for fine chemicals fluctuate based on raw material availability, energy costs, and regulatory compliance expenditures. In the current market, manufacturers offering direct factory supply can provide more stable pricing compared to traders who add multiple layers of margin.
Minimum Order Quantities (MOQ) typically align with standard industrial packaging, often starting at 25kg for commercial trials. However, for established partnerships, flexible MOQs can be negotiated to support R&D phases before scaling to multi-ton procurement. The FOB price structure generally includes:
- Base Material Cost: Dependent on the market price of precursor amines and chlorinating agents.
- Processing Fees: Covers reactor time, purification, and drying processes.
- Quality Control: Costs associated with analytical testing and documentation.
- Packaging and Logistics: Secure packaging suitable for international transport.
Buyers should request detailed quotations that separate these components to understand the true value proposition. Transparent pricing models allow procurement teams to budget effectively for long-term projects without unexpected cost variances.
Volume Discount Structures for Bulk Procurement
For pharmaceutical companies scaling up production, volume discounts are a critical component of cost management. Manufacturers typically offer tiered pricing structures that reward commitment to larger quantities. This approach ensures supply security for the buyer while optimizing production runs for the manufacturer.
A standard discount framework for this Pharmaceutical building block may look as follows:
| Order Volume | Pricing Tier | Lead Time |
|---|---|---|
| 25kg - 100kg | Standard List Price | 7-14 Days |
| 100kg - 500kg | 5% - 10% Discount | 14-21 Days |
| 500kg - 1 Ton | 10% - 15% Discount | 21-30 Days |
| 1 Ton + | Negotiated Contract Price | Scheduled Production |
These structures incentivize bulk procurement, reducing the per-unit cost significantly for large-scale API manufacturers. Additionally, long-term supply agreements can lock in prices, protecting against market volatility. It is advisable to discuss annual consumption forecasts with the supplier to tailor a discount structure that matches your production schedule.
2026 Market Forecast for Quinazoline Derivatives
Looking ahead to 2026, the demand for quinazoline-based intermediates is projected to remain stable with moderate growth. This trajectory is driven by the continued production of established cardiovascular medications and the development of new kinase inhibitors where the quinazoline scaffold is prevalent. Regulatory pressures are increasing, favoring manufacturers who can demonstrate full traceability and compliance with Good Manufacturing Practices (GMP).
Key market drivers include:
- Generic Drug Expansion: Increased production of off-patent antihypertensives in emerging markets.
- Oncology Research: Growing use of quinazoline cores in targeted cancer therapies.
- Supply Chain Regionalization: A shift towards diversified sourcing to mitigate logistical risks.
Manufacturers who invest in capacity expansion and environmental sustainability will be best positioned to capture market share. Buyers should prioritize partners with proven scalability to ensure uninterrupted supply through 2026 and beyond. The focus will shift from merely finding available stock to securing partnerships with verified global manufacturer entities that offer technical support and regulatory documentation.
Conclusion
Securing a reliable supply of CAS 23680-84-4 requires a partner who understands both the chemical intricacies and the commercial realities of the pharmaceutical industry. By focusing on industrial purity, transparent pricing, and scalable production, NINGBO INNO PHARMCHEM CO.,LTD. delivers the consistency needed for successful drug manufacturing. As the market moves toward 2026, establishing a robust supply chain for this critical API intermediate will be a key strategic advantage for pharmaceutical producers.